Market Research Logo

Xencor, Inc. - Product Pipeline Review - 2016

Xencor, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Xencor, Inc. - Product Pipeline Review - 2016’, provides an overview of the Xencor, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Xencor, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Xencor, Inc.
  • The report provides overview of Xencor, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Xencor, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Xencor, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Xencor, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Xencor, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Xencor, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Xencor, Inc. Snapshot
Xencor, Inc. Overview
Key Information
Key Facts
Xencor, Inc. - Research and Development Overview
Key Therapeutic Areas
Xencor, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Xencor, Inc. - Pipeline Products Glance
Xencor, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Xencor, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Xencor, Inc. - Drug Profiles
XmAb-5871
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 1 for Oncology
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 2 for Oncology
Product Description
Mechanism of Action
R&D Progress
XmAb-7195
Product Description
Mechanism of Action
R&D Progress
XENP-1138
Product Description
Mechanism of Action
R&D Progress
XmAb-13676
Product Description
Mechanism of Action
R&D Progress
XmAb-13677
Product Description
Mechanism of Action
R&D Progress
XmAb-14045
Product Description
Mechanism of Action
R&D Progress
XmAb-14484
Product Description
Mechanism of Action
R&D Progress
XmAb-18087
Product Description
Mechanism of Action
R&D Progress
XmAb-19722
Product Description
Mechanism of Action
R&D Progress
XmAb-20717
Product Description
Mechanism of Action
R&D Progress
XmAb-6755
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Agonize CD32b for Immunology
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Agonize CD32b for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Xencor, Inc. - Pipeline Analysis
Xencor, Inc. - Pipeline Products by Target
Xencor, Inc. - Pipeline Products by Route of Administration
Xencor, Inc. - Pipeline Products by Molecule Type
Xencor, Inc. - Pipeline Products by Mechanism of Action
Xencor, Inc. - Recent Pipeline Updates
Xencor, Inc. - Dormant Projects
Xencor, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Xencor, Inc., Key Information
Xencor, Inc., Key Facts
Xencor, Inc. - Pipeline by Indication, 2016
Xencor, Inc. - Pipeline by Stage of Development, 2016
Xencor, Inc. - Monotherapy Products in Pipeline, 2016
Xencor, Inc. - Partnered Products in Pipeline, 2016
Xencor, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Xencor, Inc. - Out-Licensed Products in Pipeline, 2016
Xencor, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Xencor, Inc. - Phase II, 2016
Xencor, Inc. - Phase I, 2016
Xencor, Inc. - Preclinical, 2016
Xencor, Inc. - Discovery, 2016
Xencor, Inc. - Pipeline by Target, 2016
Xencor, Inc. - Pipeline by Route of Administration, 2016
Xencor, Inc. - Pipeline by Molecule Type, 2016
Xencor, Inc. - Pipeline Products by Mechanism of Action, 2016
Xencor, Inc. - Recent Pipeline Updates, 2016
Xencor, Inc. - Dormant Developmental Projects,2016
Xencor, Inc., Other Locations
List of Figures
Xencor, Inc. - Pipeline by Indication, 2016
Xencor, Inc. - Pipeline by Stage of Development, 2016
Xencor, Inc. - Monotherapy Products in Pipeline, 2016
Xencor, Inc. - Partnered Products in Pipeline, 2016
Xencor, Inc. - Out-Licensed Products in Pipeline, 2016
Xencor, Inc. - Pipeline by Top 10 Target, 2016
Xencor, Inc. - Pipeline by Route of Administration, 2016
Xencor, Inc. - Pipeline by Molecule Type, 2016
Xencor, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report